Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: Results from the ASSET trial

被引:59
|
作者
Goldstein, J
Silberstein, SD
Saper, JR
Elkind, AH
Smith, TR
Gallagher, RM
Battikha, JP
Hoffman, H
Baggish, J
机构
[1] San Francisco Clin Res Ctr, San Francisco Headache Clin, San Francisco, CA 94109 USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Michigan Head Pain & Neurol Inst, Ann Arbor, MI USA
[4] Elkind Headache Ctr, Mt Vernon, NY USA
[5] Ryan Headache Ctr, Chesterfield, MO USA
[6] UMDNJ, Sch Osteopath Med, Moorestown, NJ USA
[7] Bristol Myers Squibb Co, Plainsboro, NJ USA
来源
HEADACHE | 2005年 / 45卷 / 08期
关键词
migraine; early treatment; clinical trial; sumatriptan; nonprescription medication; caffeine;
D O I
10.1111/j.1526-4610.2005.05177.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective. - To address the need for a rigorous, direct comparison of prescription and over- the-counter ( OTC) migraine drugs and to expand the database on early treatment of migraine. Background. - Most people who experience migraine use OTC medications to treat their symptoms, but no head-to-head clinical trials comparing these agents with prescription migraine therapies have been published. In addition, even though most migraineurs treat early in the attack, few studies have been conducted to reflect this treatment pattern. Methods. - We compared a combination of nonprescription migraine medication ( acetaminophen 500 mg, aspirin 500 mg, and caffeine 130 mg) with a prescription migraine product ( 50 mg sumatriptan) in a randomized, controlled clinical trial in which subjects treated at the first sign of a migraine attack. Subjectswho reported vomiting during more than 20% of migraine episodes or who required bedrest during more than 50% of migraine episodes were excluded from the study. Of the 188 subjects randomized, 171 took study medication and were included in the analysis. Conclusion. - The combination of acetaminophen, aspirin, and caffeine was significantly more effective ( P > .05) than sumatriptan in the early treatment of migraine, as shown by superiority in summed pain intensity difference, pain relief, pain intensity difference, response, sustained response, relief of associated symptoms, use of rescue medication, disability relief, and global assessments of effectiveness. An additional, larger clinical trial is needed to confirm these results.
引用
收藏
页码:973 / 982
页数:10
相关论文
共 50 条
  • [41] Preliminary Results from a Clinical Trial Comparing the Efficacy of Cefixime Versus Penicillin G for the Treatment of Early Syphilis
    Keith, Kori
    Klausner, Jeffrey D.
    Konda, Kelika A.
    Reyes-Diaz, Michael
    Stafylis, Chrysovalantis
    SEXUALLY TRANSMITTED DISEASES, 2024, 51 (01) : S376 - S377
  • [42] A RANDOMIZED DOUBLE-BLIND TRIAL OF DIHYDROERGOCRYPTINE AND CAFFEINE VERSUS PLACEBO FOR THE TREATMENT OF EARLY SYMPTOMS OF CEREBROVASCULAR INSUFFICIENCY
    POYNARD, T
    BERTHAUX, P
    GERONTOLOGY, 1986, 32 : 120 - 121
  • [43] Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin, and an early conservation initial management strategy: Results from the A phase of the A to Z trial
    de Lemos, JA
    Blazing, MA
    White, HD
    Fox, KA
    DiBattiste, PM
    Palmisano, J
    Bilheimer, DW
    Brady, WE
    Gardner, LH
    Ramsey, KE
    Lewis, EF
    Pfeffer, MA
    Califf, RM
    Braunwald, E
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 302A - 302A
  • [44] Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
    Lipton, R.
    Ashina, M.
    Tassorelli, C.
    Martin, V.
    Yu, S. Y.
    Nagy, K.
    Schwefel, B.
    Trugman, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [45] Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
    Lipton, Richard B.
    Ashina, Messoud
    Tassorelli, Cristina
    Martin, Vincent
    Yu, Sung Y.
    Nagy, Krisztian
    Schwefel, Brittany
    Trugman, Joel
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 31 - 32
  • [46] Safety and Tolerability of Ubrogepant for the Acute Treatment of Migraine in Participants Taking Atogepant for the Preventive Treatment of Episodic Migraine: Results from the TANDEM Trial
    Ailani, Jessica
    Lipton, Richard B.
    Blumenfeld, Andrew M.
    He, Molly Yizeng
    Smith, Jonathan H.
    Trugman, Joel M.
    Ferreira, Rosa de Abreu
    Brand-Schieber, Elimor
    CEPHALALGIA, 2023, 43 (1supp)
  • [47] Long Term Results of Early Surgery versus Conventional Treatment for Infective Endocarditis Trial
    Kang, Duk-Hyun
    Lee, Sahmin
    Kim, Yong-Jin
    Kim, Sung-Han
    Kim, Dae-Hee
    Yun, Sung-Cheol
    Song, Jong-Min
    Chung, Cheol-Hyun
    Song, Jae-Kwan
    Lee, Jae-Won
    KOREAN CIRCULATION JOURNAL, 2016, 46 (06) : 846 - 850
  • [48] Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial
    Chen, Jersey
    Bhatt, Deepak L.
    Dunn, Elizabeth Schneider
    Shi, Chunxue
    Caro, J. Jaime
    Mahoney, Elizabeth M.
    Gabriel, Sylvie
    Jackson, Joseph D.
    Topol, Eric J.
    Cohen, David J.
    VALUE IN HEALTH, 2009, 12 (06) : 872 - 879
  • [49] GR 43175 (SUMATRIPTAN) FOR THE TREATMENT OF ACUTE MIGRAINE .1. PRELIMINARY-RESULTS FROM AN INTERNATIONAL MULTICENTER STUDY WITH SUBCUTANEOUS ADMINISTRATION
    ENSINK, FBM
    HANEKOP, GG
    BAUTZ, M
    WEYLAND, A
    TEICHMANN, AE
    HILDEBRANDT, J
    NERVENHEILKUNDE, 1991, 10 (05) : 202 - 206